Colorectal cancer (CRC) is a prevalent disease worldwide, with more than 50% of patients
developing metastases to the liver. Five-year overall survival remains modest among …

Highlights What are the main findings? CD39-CD73 axis in tumor-associated immune cells
promotes immune exhaustion, impairment of antitumor immune activity, and increased CRC …

Background Regorafenib prolonged overall survival (OS) versus placebo in patients with
treatment-refractory metastatic colorectal cancer (mCRC) in phase III trials. We conducted an …

Background Despite the well-known negative prognostic value of the V600E BRAF mutation
in patients with metastatic colorectal cancer (mCRC), its outcome is quite heterogeneous …

Purpose: Chemotherapy plus anti-EGFR is standard first-line therapy in RAS wild-type (wt)
metastatic colorectal cancer (mCRC), but biomarkers of early response are clinically …

The association between colorectal cancer (CRC) and alterations in intestinal microbiota
has been demonstrated by several studies, and there is increasing evidence that bacteria …

Metastatic colorectal cancer (mCRC) patients have poor chances of long term survival,
being< 15% of them still alive after 5 years from diagnosis. Nonetheless, patients with …

Background The incorporation of novel biomarkers into therapy selection for patients with
metastatic colorectal cancer (m crc) has significantly improved outcomes. Optimal treatment …

Purpose The purpose of the present study was to investigate the incidence and associated
factors for early death in stage IV colorectal cancer (CRC) and to construct the predictive …

Background Retrospective subgroup analyses of previous trials in the first-line therapy of
RAS wt metastatic colorectal cancer (mCRC) suggested a predictive impact of primary …